Named Patient Program With Rotigotine Transdermal System

Completed

Conditions studied: Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine

In brief

The named patient program will allow investigators to supply rotigotine transdermal system to patients who have a documented medical necessity to receive treatment with the drug.

Key facts

Study ID

NCT01095484

Run by

UCB Pharma

People needed

520

Starts

2008-11-01

Expected to finish

2012-12-01

Last updated by the study team

2014-10-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent
• Subject is willing and able to comply with all trial requirements
• Subject either:
• is currently taking no more than 3 mg/24 h Rotigotine for Idiopathic Restless Legs Syndrome (RLS) in adults, 6 mg/24 h Rotigotine for early-stage Parkinson's disease, 8 mg/24 h Rotigotine for advanced stage Parkinson's disease (ie, treated with concomitant l-dopa) and has tried and failed an adequate course of another dopamine agonist, with failure defined as either suboptimal control of symptoms or the development of intolerable Adverse Events (AEs) (eg, hallucinations), or
• is not taking Rotigotine but has previously demonstrated an adequate response following an appropriate course of treatment with another dopamine agonist or l-dopa, based on the investigator's assessment and has tried and failed an adequate course of another dopamine agonist, or
• has completed participation in UCB Rotigotine clinical trial SP0934, SP1055, or RL0003
• The investigator attests to the medical necessity of treatment with Rotigotine in contrast to alternate treatments (eg, dysphagia).
• The investigator receives written approval from the Sponsor to enroll the subject

You may not qualify if…

• Subject is pregnant or nursing or is of child bearing potential but (i) not surgically sterile or (ii) not using adequate birth control methods or (iii) not sexually abstinent or (iv) subject is not at least 2 years postmenopausal
• Subject has any other clinically significant medical condition, psychiatric condition, or laboratory abnormality that would, in the judgment of the investigator, interfere with the subject's ability to participate in the trial
• Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C SSRS) at Screening

Where it is running

• 082 — Cullman, Alabama, United States
• 085 — Fairhope, Alabama, United States
• 014 — Huntsville, Alabama, United States
• 097 — Gilbert, Arizona, United States
• 003 — Phoenix, Arizona, United States
• 044 — Phoenix, Arizona, United States
• 036 — Berkeley, California, United States
• 024 — Fountain Valley, California, United States
• 034 — Irvine, California, United States
• 019 — Los Angeles, California, United States
• 040 — Orange, California, United States
• 076 — Sunnyvale, California, United States
• 035 — Fort Collins, Colorado, United States
• 027 — Washington D.C., District of Columbia, United States
• 070 — Atlantis, Florida, United States
• 002 — Boca Raton, Florida, United States
• 031 — Clearwater, Florida, United States
• 028 — Largo, Florida, United States
• 075 — Ormond Beach, Florida, United States
• 022 — St. Petersburg, Florida, United States
• 004 — Tampa, Florida, United States
• 054 — Weston, Florida, United States
• 030 — Atlanta, Georgia, United States
• 041 — Honolulu, Hawaii, United States
• 088 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.